Showing 3291-3300 of 3844 results for "".
- Study Highlights Skin Cancer Disparities in Hispanic/Latino Patientshttps://practicaldermatology.com/news/study-highlights-skin-cancer-disparities-in-hispaniclatino-patients/2460950/When Hispanic/Latino people are diagnosed with skin cancer, their tumors are 17 percent larger than tumors in non-Hispanic White patients, a new study shows. For the study, researchers analyzed a total of 3,486 Mohs micrographic surgeries of basal cell, squamous cell, and bas
- Long-term Extension Study Confirms Benefits of Topical Tapinarof in Psoriasishttps://practicaldermatology.com/news/long-term-extension-study-confirms-benefits-of-topical-tapinarof-in-ad/2460936/Final results from the Phase 3 PSOARING 3 long-term extension study show that Dermavant’s investigational tapinarof 1%, once daily, non-steroidal topical cream for the treatment of plaque psoriasis in adults was well tolerated long term, with a safety
- Dermavant: First Patient Dosed in Phase 3 Study of Tapinarof in ADhttps://practicaldermatology.com/news/dermavant-first-patient-dosed-in-phase-3-study-of-tapinarof-in-ad/2460925/The first patient has been dosed in the Phase 3, double-blind, vehicle-controlled pivotal study of tapinarof for the treatment of atopic dermatitis (AD). Tapinarof is an investigational, novel, therapeutic aryl hydrocarbon receptor modulating agent, in development by
- Nutrafol May Promote Hair Growth in Menopausal Womenhttps://practicaldermatology.com/news/nutrafol-may-promote-hair-growth-in-menopausal-women/2460923/Nutrafol may improve hair growth and quality for perimenopausal, menopausal, and postmenopausal women, according to research presented during The North American Menopause Society (NAMS) Annual Meeting in Washington, DC. Researchers compared results at 6 mont
- Mayne Pharma's Lexette Approved for Adolescentshttps://practicaldermatology.com/news/mayne-pharmas-lexette-approved-for-adolescents/2460921/Lexette® (halobetasol propionate) foam, 0.05% from Mayne Pharma is now approved for the treatment of plaque psoriasis in patients aged 12 years and older. FDA approved Lexette in 2018 for use in adults. Approval in adolescents is
- Incyte's Opzelura is First Topical JAK Inhibitor Approved in UShttps://practicaldermatology.com/news/incyts-opzelura-is-first-topical-jak-inhibitor-approved-in-us/2460919/Opzelura™ (ruxolitinib) cream from Incyte is now the first and only topical formulation of a JAK inhibitor approved in the United States. FDA approved Opzelura for the short-term and non-continuous chronic treatment of mild-to-moderate atopic dermatitis
- Dermala Scores New Patent Covering the Use of Human Microbiome to Prevent, Slow, and Reverse Skin Aginghttps://practicaldermatology.com/news/dermala-scores-new-patent-covering-the-use-of-human-microbiome-to-prevent-slow-and-reverse-skin-aging/2460910/Dermala has received issuance of a U.S. Patent to use the human microbiome to slow down the skin aging process. The newly patented technology uses novel microbiome formulations and delivery methods to restore biologically "younger" skin and gut microbiomes in older adult
- OncoBeta Launches Study of Rhenium-SCT for Skin Cancerhttps://practicaldermatology.com/news/oncobeta-launches-study-of-rhenium-sct-for-skin-cancer/2460909/OncoBeta GmbH is starting a phase IV international multi-centre study evaluating the complete response rate of patients with non-melanoma skin cancer after treatment with Rhenium-SCT. The Rhenium-SCT utilizes the radioisotope Rhenium-188 in an epidermal application with optimal properti
- Registration Open for ISHRS Hybrid World Congresshttps://practicaldermatology.com/news/registration-open-for-ishrs-hybrid-world-congress/2460902/The 29th Meeting of the International Society of Hair Restoration Surgery (ISHRS) is coming October 21-23. Registration is now open for the Hybrid World Congress 2021, with the i
- New Melanoma Staging System May Better Predict Prognosishttps://practicaldermatology.com/news/new-melanoma-staging-system-may-better-predict-prognosis/2460901/A new system for classifying melanoma when the disease has spread to the lymph nodes may offer a better tool for predicting patients' outcomes and determining their treatment needs, according to research in